142 related articles for article (PubMed ID: 36136021)
1. Possible Increased Risk of Death from Blood Cancer Drug.
Aschenbrenner DS
Am J Nurs; 2022 Oct; 122(10):20-21. PubMed ID: 36136021
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab approved for advanced CLL.
Traynor K
Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303
[No Abstract] [Full Text] [Related]
3. Ofatumumab.
Keating MJ; Dritselis A; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2010 Feb; 9(2):101-2. PubMed ID: 20118960
[No Abstract] [Full Text] [Related]
4. FDA Evaluating Possible Serious Risks From Umbralisib.
Aschenbrenner DS
Am J Nurs; 2022 Jun; 122(6):23. PubMed ID: 35617560
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
8. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Flinn IW; Hillmen P; Montillo M; Nagy Z; Illés Á; Etienne G; Delgado J; Kuss BJ; Tam CS; Gasztonyi Z; Offner F; Lunin S; Bosch F; Davids MS; Lamanna N; Jaeger U; Ghia P; Cymbalista F; Portell CA; Skarbnik AP; Cashen AF; Weaver DT; Kelly VM; Turnbull B; Stilgenbauer S
Blood; 2018 Dec; 132(23):2446-2455. PubMed ID: 30287523
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
10. Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
[TBL] [Abstract][Full Text] [Related]
12. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
13. Ofatumumab.
Sanford M; McCormack PL
Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
[TBL] [Abstract][Full Text] [Related]
14. Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia.
Kluger N; Cartron G; Bessis D; Guillot B; Girard C
Acta Derm Venereol; 2010; 90(1):99-100. PubMed ID: 20107742
[No Abstract] [Full Text] [Related]
15. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
Traynor K
Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
[No Abstract] [Full Text] [Related]
16. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
Coiffier B; Lepretre S; Pedersen LM; Gadeberg O; Fredriksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Flensburg M; Petersen J; Robak T
Blood; 2008 Feb; 111(3):1094-100. PubMed ID: 18003886
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
Thompson CA
Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
[No Abstract] [Full Text] [Related]
19. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Nikolaenko L; Liu T; Danilov AV
Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
[No Abstract] [Full Text] [Related]
20. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
